Home > Analytics > EMCURE PHARMACEUTICALS

EMCURE PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

BOM : 544210     NSE : EMCURE    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward
Pledged Shares : None or < 25%
Apr 11,2025
Price(EOD): ₹ 918.70
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 17,409.37 Cr
Value of ₹ 1 Lac invested in EMCURE PHARMACEUTICALS
on Jul 10,2024 (price: ₹ 1,358.85)

₹ 1 L

₹ 0.68 L

1W : -6.9% 1M : -2.3% 1Y : NA
COMMUNITY POLL
for EMCURE PHARMACEUTICALS
Please provide your vote to see the results
EMCURE PHARMACEUTICALS is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Industry Peers & Returns1W1M1Y
EMCURE PHARMACEUTICALS -6.9% -2.3% NA
SUN PHARMACEUTICAL INDUSTRIES -1.3% 4.7% 3.3%
DIVIS LABORATORIES 1.9% 1.5% 41.9%
CIPLA 3.4% 0.1% -3.1%
TORRENT PHARMACEUTICALS -4.8% 1.9% 20.3%
DR REDDYS LABORATORIES -0.1% -1% -11.3%
MANKIND PHARMA -4% 4% -1.9%
ZYDUS LIFESCIENCES 0.2% -2.8% -15.6%
LUPIN -0.1% -2% 19.1%

FUNDAMENTAL ANALYSIS OF EMCURE PHARMACEUTICALS

 
Fundamentals Score
[ Q(TTM): Dec2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 EMCURE is one of the top 37% companies with good fundamentals ! Discover More →

VALUATION OF EMCURE PHARMACEUTICALS

 
Valuation Score
[As on : Apr 11,2025 ]

Ratio Consolidated
P/E
P/B
P/S
27.63
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 629.99 Cr
[Latest Qtr - Dec2024 - Consolidated Results ]

5.93
P/B Calculated based on Book Value of Rs 2,937.79 Cr
[Latest Year - Mar2024 - Consolidated Results ]

2.34
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 7,447.40 Cr
[Latest Qtr - Dec2024 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 22% undervalued companies ! Discover More →

FAIR VALUE OF EMCURE PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
22307%
2616%
-

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF EMCURE PHARMACEUTICALS



EMCURE PHARMACEUTICALS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF EMCURE PHARMACEUTICALS

Year Debt/Equity ratio
Standalone Consolidated
2024
2023
2022
Avg_3yrs
0.73
0.91
0.93
0.86
0.71
0.88
1.05
0.88
[Last Annual Data : Mar2024]
Financial Ratios →

PLEDGED PROMOTER SHARES OF EMCURE PHARMACEUTICALS

Pledged Promoter Shares
0 %
As on : Dec2024

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF EMCURE PHARMACEUTICALS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-1.97%
-6.9%
-15.91%
-22.55%
18.01%
7.77%
16.11%
7.03%
QtrlyTrend
0
Latest Qtr: Dec2024
Quarterly Result Analysis →


EMCURE PHARMACEUTICALS related INDICES

BSE Indices1W1M1Y
BSE LARGEMIDCAP -2.2% 1.5% -0.2%
BSE HEALTHCARE -3.5% 2.1% 13.7%
BSE MIDSMALLCAP -3.6% 0.7% -0.9%
BSE MIDCAP -3.6% 1% -1.4%
BSE IPO -4% -3.7% -7.4%
NSE Indices1W1M1Y
NIFTY 500 -2.3% 1.5% 0.2%
NIFTY TOTAL MARKET -2.4% 1.4% 0.2%
NIFTY500 MULTICAP 50:25:25 -2.6% 1.5% -0.1%
NIFTY MIDSMALLCAP 400 -3.3% 1.6% -0.6%
NIFTY SMALLCAP 250 -3.3% 1.3% -3%

You may also like the below Video Courses


FAQ about EMCURE PHARMACEUTICALS


Is EMCURE PHARMACEUTICALS good for long term investment?

As on Apr 11,2025, the Fundamentals of EMCURE PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of EMCURE PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is EMCURE PHARMACEUTICALS UnderValued or OverValued?

As on Apr 11,2025, EMCURE PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of EMCURE PHARMACEUTICALS ?

As on Apr 11,2025, the Intrinsic Value of EMCURE PHARMACEUTICALS is Rs. 18.96 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 4.10
Fair Value [Median EV / Sales Model] : Rs. 33.82
Fair Value [Median Price / Sales Model] : Rs. 0.00
Estimated Median Fair Value of EMCURE PHARMACEUTICALS : Rs. 18.96

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is EMCURE PHARMACEUTICALS trading at a Premium or Discount?

As on Apr 11,2025, EMCURE PHARMACEUTICALS is trading at a Premium of 4745% based on the estimates of Median Intrinsic Value!